- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03881917
Cystatin c and Beta 2 Microglobulin in Thalassemic Children.
March 18, 2019 updated by: Mohamed Naguib Khairy, Assiut University
Cystatin C and Beta 2 Microglobulin as Biochemical Markers for Early Detection of Renal Impairment in Children With Beta Thalassemia
Beta thalassemia has many complications on many systems as the renal system.So early detection of renal impairment is required in those children to decrease complications of this nephropathy.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Thalassemia syndromes are the most common single gene disorders worldwide especially in developing countries.
The use of regular and frequent blood transfusions in patients with beta thalassemia major has improved patients' life spans and quality of life, but can lead to chronic iron overload.
Many factors contribute to the functional abnormalities found in beta thalassemia patients such as decreased red cell life span, rapid iron turnover, tissue deposition of excess iron and also, specific iron chelators can affect kidneys.
The success in management of patients of beta thalassemia has led to chronic hemosiderosis in different organs like liver and heart and long-term complications in other organs like pancreas and kidneys have recently been studied.
The evidence of proximal tubular damage has been observed in beta thalassemia patients.
Also, low-molecular-weight proteinuria has been found in almost all patients.
Unlike other organs, it is unclear whether kidney damage results solely from intravascular haemolysis, chronic transfusion or as a complication of iron chelation therapy.
Although the early identification of patients at high risk of renal impairment is of great importance as it may allow specific measures to be taken to delay renal impairment, there are limited studies about renal dysfunction in pediatric thalassemic patients.
Thus, in this study we will use different measurements for early detection of renal impairment even if the patients have no symptoms to handle with the disease in its reversible stage before being irreversible.
Beside the usual investigations of renal function we will measure cystatin c and beta2 microglobulin as early markers of renal impairment.
Study Type
Observational
Enrollment (Anticipated)
150
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mohamed Naguib Khairy, M.B.B.Ch
- Phone Number: +201091921973
- Email: mohamed_ibrahim@med.au.edu.eg
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Children with beta thalassemia from the age of 1 year to 18 years.
Description
Inclusion Criteria:
- Children with beta thalassemia from the age of 1 year to 18 years.
Exclusion Criteria:
- Children who have other hematological or chronic disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
mean difference of cystatin c and beta 2 microglobulin concentrations with normal range
Time Frame: baseline
|
Analysis of the results to differentiate the affected from non affected patients
|
baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- den Bakker E, Gemke RJBJ, Bokenkamp A. Endogenous markers for kidney function in children: a review. Crit Rev Clin Lab Sci. 2018 May;55(3):163-183. doi: 10.1080/10408363.2018.1427041. Epub 2018 Feb 1.
- Annayev A, Karakas Z, Karaman S, Yalciner A, Yilmaz A, Emre S. Glomerular and Tubular Functions in Children and Adults with Transfusion-Dependent Thalassemia. Turk J Haematol. 2018 Mar 1;35(1):66-70. doi: 10.4274/tjh.2017.0266. Epub 2017 Jul 28.
- Behairy OG, Abd Almonaem ER, Abed NT, Abdel Haiea OM, Zakaria RM, AbdEllaty RI, Asr EH, Mansour AI, Abdelrahman AM, Elhady HA. Role of serum cystatin-C and beta-2 microglobulin as early markers of renal dysfunction in children with beta thalassemia major. Int J Nephrol Renovasc Dis. 2017 Sep 11;10:261-268. doi: 10.2147/IJNRD.S142824. eCollection 2017.
- Deveci B, Kurtoglu A, Kurtoglu E, Salim O, Toptas T. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Ann Hematol. 2016 Feb;95(3):375-81. doi: 10.1007/s00277-015-2561-2. Epub 2015 Nov 23.
- Hashemieh M, Radfar M, Azarkeivan A, Hosseini Tabatabaei SMT, Nikbakht S, Yaseri M, Sheibani K. Renal Hemosiderosis among Iranian Transfusion Dependent beta-Thalassemia Major Patients. Int J Hematol Oncol Stem Cell Res. 2017 Apr 1;11(2):133-138.
- Ali BA, Mahmoud AM. Frequency of glomerular dysfunction in children with Beta thalassaemia major. Sultan Qaboos Univ Med J. 2014 Feb;14(1):e88-94. doi: 10.12816/0003341. Epub 2014 Jan 27.
- Bakr A, Al-Tonbary Y, Osman G, El-Ashry R. Renal complications of beta-thalassemia major in children. Am J Blood Res. 2014 Sep 5;4(1):1-6. eCollection 2014.
- Uzun E, Balci YI, Yuksel S, Aral YZ, Aybek H, Akdag B. Glomerular and tubular functions in children with different forms of beta thalassemia. Ren Fail. 2015;37(9):1414-8. doi: 10.3109/0886022X.2015.1077314. Epub 2015 Sep 12.
- Nickavar A, Qmarsi A, Ansari S, Zarei E. Kidney Function in Patients With Different Variants of Beta-Thalassemia. Iran J Kidney Dis. 2017 Mar;11(2):132-137.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2019
Primary Completion (Anticipated)
November 1, 2020
Study Completion (Anticipated)
March 1, 2021
Study Registration Dates
First Submitted
March 18, 2019
First Submitted That Met QC Criteria
March 18, 2019
First Posted (Actual)
March 20, 2019
Study Record Updates
Last Update Posted (Actual)
March 20, 2019
Last Update Submitted That Met QC Criteria
March 18, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Renal markers in thalassemia.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Disease
-
Assistance Publique Hopitaux De MarseilleNot yet recruitingBlood Platelet Disease
-
University of New MexicoNational Heart, Lung, and Blood Institute (NHLBI)TerminatedBlood Disease | Blood Donors
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Diseases | Cardiovascular Diseases | Lung Diseases | Blood Disease
-
University of UlsterCompletedBlood PressureUnited Kingdom
-
Azienda Ospedaliera San Giovanni BattistaUnknown
-
University of Wisconsin, MadisonUniversity of Wisconsin Carbone Cancer Center (UWCCC)Not yet recruiting
-
Hamad Medical CorporationSidra Medical and Research Center; World Anti-Doping Agency; Anti-Doping Lab... and other collaboratorsUnknownBlood Disease | Blood Transfusion, Autologous | Blood Doping | Blood Transfusion, HomologousQatar
-
Archemix Corp.Withdrawn
-
Uniform Data System for Medical RehabilitationTerminatedNervous System Diseases | Wounds and Injuries | Heart and Blood Disease | Muscle, Bone and Cartilage Disease | Skin and Connective Tissue DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedAnemia | Blood Disease
Clinical Trials on Cystatin c and beta 2 microglobulin kits
-
University Hospital, Basel, SwitzerlandCompletedRenal Biomarkers in ChildrenSwitzerland
-
Chang Gung Memorial HospitalRecruiting
-
Cairo UniversityCompletedHypertension | Diabetes | Hepatitis C, AcuteEgypt
-
Assiut UniversityUnknownAcute Kidney Injury
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)Completed
-
Sahlgrenska University Hospital, SwedenCompletedRenal Insufficiency | Hip Fractures | Hypotension | Heart InjuriesSweden
-
Ain Shams UniversityCompletedBiochemical Markers ,NGAL,Cystatin c, Acute Kidneyinjury, Covid 19Egypt
-
National Cancer Institute (NCI)Suspended
-
Assiut UniversityUnknownPostoperative Acute Kidney Injury
-
Karolinska University HospitalActive, not recruiting